DOI:
10.1055/s-00000059
Pneumologie
LinksClose Window
References
Zhou C, Wu YL, Chen G. et al.
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802).
Ann Oncol 2015;
26: 1877-1883
DOI: 10.1093/annonc/mdv276.
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.